Clinical dilemmas in non-alcoholic fatty liver disease / (Record no. 6920)

MARC details
000 -LEADER
fixed length control field 03965cam a2200397 i 4500
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20240305192445.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m |o d |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr_|||||||||||
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 151019s2016 enk ob 001 0 eng
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER
LC control number 2015041033
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781118924952 (ePub)
International Standard Book Number 9781118924976 (Adobe PDF)
Canceled/invalid ISBN 9781118912034 (pbk.)
040 ## - CATALOGING SOURCE
Original cataloging agency DLC
Language of cataloging eng
Transcribing agency DLC
Description conventions rda
Modifying agency DLC
042 ## - AUTHENTICATION CODE
Authentication code pcc
050 00 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC848.F3
060 10 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER
Classification number WI 700
082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.3/62
Edition information 23
245 00 - TITLE STATEMENT
Title Clinical dilemmas in non-alcoholic fatty liver disease /
Statement of responsibility, etc. [edited by] Roger Williams, Simon Taylor-Robinson.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Chichester, West Sussex, UK ;
-- Hoboken, NJ :
Name of producer, publisher, distributor, manufacturer John Wiley & Sons Inc.,
Date of production, publication, distribution, manufacture, or copyright notice 2016.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource.
336 ## - CONTENT TYPE
Content type term text
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Source rdacarrier
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc. note Includes bibliographical references and index.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Hype or harm from fatty liver disease? / Stephen H Caldwell and Curt Argo -- Worldwide problem / Geoffrey Farrell and Philip Newsome -- Is insulin resistance the key motive for NAFLD? / Desmond Johnston -- Progression to cirrhosis is more likely in children with NAFLD? / Anil Dhawan -- NAFLD as cause of cryptogenic cirrhosis? / Jay Lefkowitch -- Is NAFLD different in absence of metabolic syndrome? / Yusuf Yilmaz -- Occurrence of noncirrhotic HCC in NAFLD / Stephen Harrison and Dawn Torres -- Fibrosis progression molecular pathways all important? / Anna-Mae Diehl and Dr Wing-Kin Syn -- Can fatty liver of NAFLD be distinguished from that of alcoholic liver disease? / David Kleiner and Elizabeth Brunt -- Are inflammasomes and intestinal microbiota relevant in disease progression to NASH? / M. Bilal Siddiqui, M. Shadab Siddiqui and Arun Sanyal -- Can genetic influence in non-alcoholic fatty liver disease be ignored? / Quentin Anstee -- Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events? / Soo Lim -- Is there a best method for diagnosis of NAFLD? / Vlad Ratziu -- Choice of non-invasive blood tests and FibroScan / Massimo Pinzani and Manolis Tsocatzis -- Are the guidelines AASLD, IASL, EASL and BSG of help? / Jean-Francois Dufour -- How to choose from different imaging modalities and screening techniques / Hero Hussain -- Are the pros outweighed by the cons of obtaining a liver biopsy? / Simon Taylor-Robinson and Jeremy Cobbold -- Screening for NAFLD in high risk population / Nader Lessan -- Balancing calorie restriction, exercise and weight reduction / Nicholas Finer -- Should physicians be prescribing, or patients self-medicating with Orlistat, vitamin E, vitamin D, insulin antagonist, Trental and coffee? / Brent Neuschwander-Tetri and Haripriya Maddur -- Does improvement in hepatic steatosis have a significant favourable effect on the metabolic syndrome, including diabetes? / Jukka Westerbacka -- What are the dangers as well as the true benefits of bariatric surgery? / Andrew Jenkinson -- Liver transplantation : what can it offer? / Roger Williams -- Molecular antagonists, leptin or other hormones in supplementing environmental factors? / Jeremy Tomlinson -- Use of antifibrotic agents in clinical practice / Jonathan Fallowfield -- Better understanding of early development and material influence? / Jude Oben -- Defining the role of metabolic physician / Nicholas Finer.
588 ## - SOURCE OF DESCRIPTION NOTE
Source of description note Description based on print version record and CIP data provided by publisher.
650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM
9 (RLIN) 38451
700 1# - ADDED ENTRY--PERSONAL NAME
Dates associated with a name 1931- ,
Relator term editor.
9 (RLIN) 38452
Relator term author.
9 (RLIN) 38453
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Print version:
Title Clinical dilemmas in non-alcoholic fatty liver disease
Place, publisher, and date of publication Chichester, West Sussex ; Hoboken, NJ : John Wiley & Sons Inc., 2016
International Standard Book Number 9781118912034
Record control number (DLC) 2015040510
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
a 7
b cbc
c origcop
d 1
e ecip
f 20
g y-gencatlg
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme ddc
Koha item type E-BOOKS
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Collection Home library Current library Shelving location Date acquired Total checkouts Full call number Barcode Date last seen Price effective from Koha item type
            MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO   06/06/2022   616.3/62 EBS11390 06/06/2022 06/06/2022 E-BOOKS
Catholic University of  Health and Allied Sciences - CUHAS
Directorate of ICT @ 2024